SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 4

Do bone morphogenic protein-4 antagonists have any role in the treatment of human hypertension?

Kemik morfojenik protein-4 antagonistleri insanlarda hipertansiyonun tedavisinde kullanılabilir mi?

Ali E. DENKTAŞ
Ekrem YETER
Bülent ÖZÇAKAR
Mustafa KURT
Pages
356–357
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

DENKTAŞ, A. E., YETER, E., ÖZÇAKAR, B., KURT, M. (2022). Do bone morphogenic protein-4 antagonists have any role in the treatment of human hypertension?. Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 4, 356–357. https://ajindex.com/articles/436940

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Wozney JM. The morphogenetic protein family: Multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci 1998; 106: 160-6
  2. Winnier G, Blessing M, Labosky PA, Hogan BLM. Bone morphogenetic protein 4 is required for mesoderm formation and patterning in the mouse. Genes Dev 1995; 9: 2105-16
  3. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-9
  4. Miriyala S, Gongora Nieto MC, Mingone C, Smith D, Dikalov S, Harrison DG, et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 2006; 113: 2818-25
  5. Bäumer AT, Krüger CA, Falkenberg J, Freyhaus HT, Rösen R, Fink K, et al. The NADPH oxidase inhibitor apocynin improves endothelial NO superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade. Clin Exp Hypertens 2007; 29: 287-99.